With ImmunoCellular Therapeutics (NYSE MKT: IMUC)
NBS' subsidiary, Progenitor Cell Therapy (PCT), and ImmunoCellular Therapeutics (NYSE MKT: IMUC) ("IMUC executed a Services Agreement under which PCT will provide cGMP manufacturing services to support R&D of IMUC's ICT-121 cell therapy product candidate, a dendritic cell vaccine targeting CD133 cells.
The Bottom Line: PCT currently provides manufacturing services for IMUC's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma, for its P2 clinical trial. With its East and West Coast facilities … PCT has unique expertise in manufacturing, regulatory, logistical transport and commercialization for therapeutics development.
NBS closed on 5/31/13 at $0.56; so expect a few cents <+$0.01 - $0.03 appreciation <look to the last such announcement and up-ward move> on 5/13/13 <Georgetown over 2 days>and as the short interest is at its lowest in over 18 months plus an UP market!
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.